Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
A retrospective cohort study was carried out in a large Israeli health maintenance organization to determine vaccine effectiveness (VE) of a third dose of BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of nearly 1 million members receiving 2 doses of BNT162b2 in January–February 2021, infection rates (based on polymerase chain reaction results) were compared between those who received a third dose with those who did not during August–October 2021 (maximum, 70 days). Crude VE was 92.9% (95% confidence interval [CI], 92.6%–93.2%) and adjusted VE was 89.1% (95% CI, 87.5%–90.5%). We conclude that the third dose provides added protection against SARS-CoV-2 infection for those vaccinated 6 months ago.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×
“Initial population-based studies in Israel comparing the vaccinated and unvaccinated reported VE rates of 95% [4, 5].”
BackgroundHaas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564 · cited 1×
“Initial population-based studies in Israel comparing the vaccinated and unvaccinated reported VE rates of 95% [4, 5].”
BackgroundProtection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169
Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02183-8 · Cited by 1,167 · cited 3×
“The Israel Ministry of Health implemented a second national vaccination campaign in August 2021, providing a third dose of the BNT162b2 vaccine, after studies [6] indicated that protection against SARS-CoV-2 was waning 6 months after the first national vaccination campaign.”
BackgroundMethodPatalon, T., Gazit, S., Pitzer, V. E., Prunas, O., Warren, J. L., & Weinberger, D. M. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7382 · Cited by 141
Cited by
SARS‐CoV‐2 Omicron variant: Characteristics and prevention
He, X., Hong, W., Pan, X., Lu, G., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.110 · Cited by 506
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Tang, P., Hasan, M. R., Coyle, P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200797 · Cited by 380
Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Zhang, N.-N., Zhang, R.-R., Zhang, Y.-F., Ji, K., Xiong, X.-C., Qin, Q.-S., Gao, P., Lu, X.-S., Zhou, H.-Y., Song, H.-F., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00626-w · Cited by 47
Naito, T., Tsuchida, N., Kusunoki, S., Kaneko, Y., Tobita, M., Hori, S., & Ito, S. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2093722 · Cited by 22
“1% after statistical adjustment for patient demographics [15], and the effective-”
Background
Metadata
- Authors
- Saciuk, Y., Kertes, J., Shamir Stein, N., & Ekka Zohar, A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-11-02
- Volume
- 225
- Issue
- 1
- Pages
- 30-33
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W3211197905
- Cited by
- 74
- References
- 6
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine. https://app.cochat.ai/papers/10.1093/infdis/jiab556
- The paper
- Saciuk, Y., Kertes, J., Shamir Stein, N., & Ekka Zohar, A. (2022). Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiab556
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.